Oral urea: the tool we need to address the morbidity associated with chronic hyponatremia in the multi-pathological geriatric patient
DOI:
https://doi.org/10.32818/reccmi.a9s1a6Keywords:
hyponatremia, SIADH, urea, geriatrics, oral therapyAbstract
Oral urea treatment emerges as an effective and safe option for managing chronic hyponatremia in geriatric patients with multiple comorbidities, particularly in those with syndrome of inappropriate antidiuretic hormone secretion (SIADH). A case of an 84-year-old patient is presented, where urea treatment significantly improved neurocognitive function and reduced hospital readmissions, highlighting its importance for this vulnerable population.
Downloads
Metrics
References
Martin-Grace J, Tomkins M, O'Reilly MW, Thompson CJ, Sherlock M. Approach to the patient: hyponatremia and the syndrome of inappropriate antidiuresis (SIAD). J Clin Endocrinol Metab. 2022; 107(8): 2362-2376. doi: https://doi.org/10.1210/clinem/dgac245 (último acceso sept. 2024). DOI: https://doi.org/10.1210/clinem/dgac245
Thorpe O, Cuesta M, Fitzgerald C, Feely O, Tormey WP, Sherlock M, et al. Active management of hyponatraemia and mortality in older hospitalised patients compared with younger patients: results of a prospective cohort study. Age Ageing. 2021; 50(4): 1144-1150. doi: https://doi.org/10.1093/ageing/afaa248 (último acceso sept. 2024). DOI: https://doi.org/10.1093/ageing/afaa248
Suárez V, Norello D, Sen E, Todorova P, Hackl MJ, Hüser C, et al. Impairment of neurocognitive functioning, motor performance, and mood stability in hospitalized patients with euvolemic moderate and profound hyponatremia. Am J Med. 2020; 133(8): 986-993.e5. doi: https://doi.org/10.1016/j.amjmed.2019.12.056 (último acceso sept. 2024). DOI: https://doi.org/10.1016/j.amjmed.2019.12.056
Refardt J, Kling B, Krausert K, Fassnacht M, von Felten S, Christ-Crain M, et al. Impact of chronic hyponatremia on neurocognitive and neuromuscular function. Eur J Clin Invest. 2018; 48(11): e13022. doi: https://doi.org/10.1111/eci.13022 (último acceso sept. 2024). DOI: https://doi.org/10.1111/eci.13022
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014; 170(3): G1-47. doi: https://doi.org/10.1530/EJE-13-1020 (último acceso sept. 2024). DOI: https://doi.org/10.1093/ndt/gfu040
Barajas Galindo DE, Ruiz-Sánchez JG, Fernández Martínez A, de la Vega IR, Ferrer García JC, Ropero-Luis G, et al. Consensus document on the management of hyponatraemia of the Acqua Group of the Spanish Society of Endocrinology and Nutrition. Endocrinol Diabetes Nutr (Engl Ed). 2023; 70(Suppl1): 7-26. doi: https://doi.org/10.1016/j.endien.2022.11.006 (último acceso sept. 2024). DOI: https://doi.org/10.1016/j.endien.2022.11.006
Perelló-Camacho E, Pomares-Gómez FJ, López-Penabad L, Mirete-López RM, Pinedo-Esteban MR, Domínguez-Escribano JR. Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion. Sci Rep. 2022; 12(1): 10266. doi: https://doi.org/10.1038/s41598-022-14387-4 (último acceso sept. 2024). DOI: https://doi.org/10.1038/s41598-022-14387-4
Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol. 2012; 7(5): 742-747. doi: https://doi.org/10.2215/CJN.06990711 (último acceso sept. 2024). DOI: https://doi.org/10.2215/CJN.06990711
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 María Dolores Hernández-Rabadán
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
